Sept 26 (Reuters) – French drugmaker Sanofi and
its U.S. partner Regeneron Pharmaceuticals could win
U.S. approval for their keenly awaited new eczema drug
dupilumab, seen by analysts as a potential…
The post Sanofi may win U.S. approval of $3 bln eczema drug by March appeared first on NASDAQ.